kzr-261
·Code: KZR-261
kzr-261: developed by 1 company · 1 clinical trial tracked. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Kezar Life Sciences, Inc. (KZR) | Phase 1 |
Clinical Trials (1)
A Phase 1 Study of KZR-261, a Small Molecule Sec61 Inhibitor, in Subjects With Advanced Solid Malignancies
Frequently asked questions
Who is developing kzr-261?
kzr-261 is being developed by Kezar Life Sciences, Inc..
How many clinical trials involve kzr-261?
BioSniper tracks 1 clinical trial involving kzr-261.
Get deeper analysis on kzr-261
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis